WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals, Inc. (ALNY), a RNAi therapeutics company, on Tuesday announced the pricing of its previously announced private offering of $900 million of 1 percent
WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals Inc. (ALNY) announced positive results from the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment
-Treatment with Cemdisiran Resulted in a Higher Proportion of Patients Achieving Clinically Meaningful Reductions in 24-Hour Urine Protein to Creatinine Ratio, as Compared to Patients on Placebo -
PARIS (dpa-AFX) - Alnylam Pharmaceuticals Inc. (ALNY) said that the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated
AMSTERDAM (dpa-AFX) - The following are some of the healthcare companies that reported quarterly financial results and provided an update on their pipeline progress on Thursday.1. ALNY Q2 Loss